前收市價 | 3.5800 |
開市 | 3.6300 |
買盤 | 3.6800 x 300 |
賣出價 | 3.7100 x 5600 |
今日波幅 | 3.6300 - 3.8000 |
52 週波幅 | 1.6400 - 4.0500 |
成交量 | |
平均成交量 | 12,617,530 |
市值 | 2.164B |
Beta 值 (5 年,每月) | 0.61 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -0.3200 |
業績公佈日 | 2024年5月09日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 5.08 |
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Geron Corp (NASDAQ:GERN) shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia. What Happened: After the market close on Thursday, Geron announced that ODAC voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusio